Unaudited Financial Result for the half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 1.9 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amkay Products Limited reported its H1 FY26 (Apr-Sep 2025) results, with revenue from operations rising to ₹2,301.14 lakhs from ₹1,783.82 lakhs in H1 FY25, a growth of about 29% year-on-year. Total income stood at ₹2,340.45 lakhs versus ₹1,856.33 lakhs earlier. Profit after tax came in at ₹196.80 lakhs, up roughly 8% from ₹182.53 lakhs, translating to an EPS of ₹2.33 (vs ₹2.24). However, total expenses grew faster than revenue, causing EBITDA margin to compress to around 14.4% from 16.8% last year. The statutory auditor issued an unmodified (clean) limited review opinion on the results.
Strong top-line growth is a positive for the stock, but the noticeable margin compression and only modest bottom-line growth suggest rising costs are eating into profitability. Investors should watch whether the company can convert its revenue momentum into better earnings in the coming quarters.